Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Claudia Abletshauser"'
Autor:
Ulrich Tebbe, Sylvia Haas, Claudia Abletshauser, Christian Sieder, Sebastian Schellong, Peter Bramlage, Horst Eberhard Gerlach, Hanno Riess
Publikováno v:
American Heart Journal. 161:322-328
Despite the elevated risk for developing venous thromboembolic events in patients with heart failure, there are no randomized, double-blind, controlled trial data on the comparison of low-molecular-weight heparin with unfractionated heparin (UFH) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::553630f5c83577af4739a7ab4f630856
https://doi.org/10.1016/j.ahj.2010.10.005
https://doi.org/10.1016/j.ahj.2010.10.005
Autor:
Sebastian Schellong, Sylvia Haas, Claudia Abletshauser, H. Gerlach, Nima Melzer, Rupert Bauersachs, Christian Sieder, Ulrich Tebbe, Peter Bramlage, Hanno Riess
Publikováno v:
Thrombosis and Haemostasis. 105:981-988
SummaryPatients with severe renal insufficiency (sRI) have been suggested to be at an increased risk of bleeding with low-molecular-weight heparins (LMWH). We aimed at assessing the benefits and risks of certoparin in comparison to unfractionated hep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baa706148e20597b1fd7425b10769cfa
https://doi.org/10.1160/th10-09-0614
https://doi.org/10.1160/th10-09-0614
Publikováno v:
Coronary Artery Disease. 20:81-85
BACKGROUND Postprandial lipemia is known to exert a reversible detrimental effect on endothelium-dependent flow-mediated vasodilation (FMD). Fasting FMD has shown to be improved by fluvastatin. In this study, we investigated whether lipemia-induced e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4efcb8193e54a31d52253cd31d29e75d
https://doi.org/10.1097/mca.0b013e32831a8811
https://doi.org/10.1097/mca.0b013e32831a8811
Autor:
Jonathan L. Isaacsohn, Christoph Wanner, Claudio Gimpelewicz, Hallvard Holdaas, Claudia Abletshauser
Publikováno v:
International Journal of Cardiology. 117:64-74
Individuals with chronic kidney disease are at high risk for cardiovascular disease and have a high prevalence of hyperlipidemia. Lipid-lowering therapy may help patients with renal disease reduce their risk for cardiovascular events.A pooled analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd78593346c0840bab22e4bbd1deb53c
https://doi.org/10.1016/j.ijcard.2006.06.003
https://doi.org/10.1016/j.ijcard.2006.06.003
Autor:
Winfried März, Claudia Abletshauser, Tatjana Stojakovic, Hubert Scharnagl, Monika Vogel, Franz Freisinger
Publikováno v:
Cardiology. 106:241-248
Background: Flexibility in the time of administration of statin therapy is likely to improve patient compliance. This study compared the efficacy and tolerability of morning and evening administration of the extended-release formulation of fluvastati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f4ee07cc0fd244c041e4c1645869966
https://doi.org/10.1159/000093200
https://doi.org/10.1159/000093200
Autor:
Winfried März, Aloys Berg, Heinrich Wieland, Hubert Scharnagl, Manfred W. Baumstark, Claudia Abletshauser, Michael Hoffmann, Joseph Keul
Publikováno v:
Circulation. 103:1942-1948
Background —Although HMG-CoA reductase inhibitors (HMGRIs) are effective lipid-lowering agents, it remains controversial whether these agents also lower dense LDL (dLDL), a predominance of which is considered to contribute to the atherogenicity of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::717063064b0cc70d780d4278751668cd
https://doi.org/10.1161/01.cir.103.15.1942
https://doi.org/10.1161/01.cir.103.15.1942
Autor:
Nicole Martin, Klaus Kusterer, E. Haak, Thomas Haak, Klaus Henning Usadel, Notbert Hermanns, Karl J. Lackner, Sonja Weber, Claudia Abletshauser, Christine Goedicke
Publikováno v:
Atherosclerosis. 155:395-401
The purpose of this study was to investigate the effect of fluvastatin on the microcirculation of patients with hyperlipidaemia (low-density lipoprotein cholesterol > 160 mg/dL, triglycerides < 350 mg/dl) inadequately controlled by diet. After a diet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::102795e9bad56ae88ef78f1a32e0ebd0
https://doi.org/10.1016/s0021-9150(00)00567-0
https://doi.org/10.1016/s0021-9150(00)00567-0
Publikováno v:
Thrombosis Research. 95:229-234
We have investigated the effects of a potent lipid-lowering therapy on the activity of platelets as measured ex vivo by the surface activation markers CD62 (PADGEM, P-selectin, GMP 140) and CD63 (GP53) in a double-blind, randomized, placebo-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9ca40ecd8835ac54c0657e5630664a1
https://doi.org/10.1016/s0049-3848(99)00037-7
https://doi.org/10.1016/s0049-3848(99)00037-7
Autor:
H. Caroline Gertzen, I. Blankoff, Christian Torp-Pedersen, Stephane Carlier, Vedat Davutoglu, Ozlem Soran, Judeen Camacho, Lisette Okkels Jensen, Janos Molnar, Liang-Yu Lin, Claudia Abletshauser, Meir Antopolsky, Gergana Stoschitzky, Giuseppe Tarantini, Tova Chajek-Shaul, Kirsten Tolstrup, Jens Haarbo, Paolo Bruzzi, Kemal Yeşilçimen, Sabino Iliceto, Helmut Brussee, S.E. Haine, Stephen D. Greenwood, C.J. Vrints, Bo E. Madsen, Ayşe Emre, Robert J. Siegel, Per Thayssen, Serdar Soydinc, Harald Dobnig, Gary S. Mintz, John C. Somberg, Peter A. Smars, V. Ranade, Yen-Wen Wu, Jai-Wun Park, Hubert Scharnagl, Ming-Fong Chen, Torben Haghfelt, Domenico Scrutinio, David Leibowitz, Monika Vogel, Juey-Jen Hwang, Jawdat Abdulla, Birsen Ersek, H.P. Miljoen, Jose A. Ruiz, Mehmet Aksoy, Lars Køber, Jiunn-Lee Lin, Ivana Cvetanovic, Knud Erik Pedersen, Tamer Akbulut, Tatjana Stojakovic, Luca Boni, Winfried März, Ayhan Dundar, Zita Molnar, Dilaver Oz, Claudia Bonell, Tal Hasin, Kurt Stoschitzky, Hsiang-Yiang Jui, Sait Terzi, Nurten Sayar, Franz Freisinger, Paolo Rizzon, Chii-Ming Lee, Yuan-Teh Lee, Tuba Bilsel, Jou-Wei Lin, Ekrem Ucer
Publikováno v:
Cardiology. 106:283-285
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d89dd3c078cc5a2b31f61fa3e62110d
https://doi.org/10.1159/000097150
https://doi.org/10.1159/000097150
Autor:
D. Meissner, Peter Lattke, Claudia Abletshauser, T. Kurktschiev, Hanefeld M, W. Jaross, Leonhardt W, G. Weidinger
Publikováno v:
European Journal of Clinical Pharmacology. 53:65-69
Oxidation of low density lipoproteins (LDL) is thought to be an important step in the development of atherosclerosis. Trace metals are involved in oxidative processes. It was of interest to determine whether lipid-lowering therapy with fluvastatin, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::807c634e60978bd3dd687af69f305af1
https://doi.org/10.1007/s002280050338
https://doi.org/10.1007/s002280050338